AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alexion Pharma

Foamix Pharmaceuticals

The FDA has cleared three therapies since Friday, sending shares of the sponsor companies higher Monday morning.

3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.

What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?

AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC.

AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review

The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study

AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.

AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA

AstraZeneca achieved positive results in treating metastatic castration-resistant prostate cancer patients with a specific molecular biomarker.

AstraZeneca Makes Great Prostate Cancer Treatment Showing, Targeting Specific Molecular Biomarker Patients

Merck

AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.

AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study

Nanomedicine formulation of Astra Zeneca potential best in class Bcl2/xL cancer drug, approved for clinical trials by FDA.

FDA Clearance For Astra Zeneca/Starpharma Potential Blockbuster Cancer Drug

AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.

AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study

GlaxoSmithKline

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients.

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why AstraZeneca (AZN) is Outperforming Its Industry

The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.

AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet

Eli Lilly

Novo Nordisk

Here's what investors need to know about a new injection-free, non-insulin treatment for type 2 diabetes.

Meet the Revolutionary New Diabetes Drug You've Probably Never Heard Of

Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.

Ironwood Amends Linzess Agreement with AstraZeneca in China

The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.

AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

AstraZeneca had recently reported a positive outcome using its cancer drug Imfinzi along with standard of care chemotherapy to treat patients with front-line extensive-stage SCLC.

AstraZeneca's Latest Lung Cancer Test Data Makes It A Force To Be Reckoned With

Bristol-Myers

Pfizer

We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

4 Big Drugmakers Boasting Impressive Oncology Pipelines

New data came out for AstraZeneca's diabetes drug Farxiga showing it helps all people with heart failure, diabetic or not.

AstraZeneca At All-Time Highs With Much More Room To Run

AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.

AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC

AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.

AstraZeneca's Lupus Drug Meets Primary Endpoint in Study

AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.

AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease

The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.

AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome

AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.

News for AstraZeneca Stock (AZN)